Figure 3.
LIC (mg/g dw)† for deferiprone and deferoxamine treatment groups for the ITT population (primary endpoint). (A) LIC over time. Data are shown as means with error bars showing SD. (B) Mean change in LIC from baseline at month 12. Data are shown as means with error bars showing SE. A t test was used to calculate the P value. †LIC was measured using R2* MRI scans, which were performed at screening/baseline, month 6, and month 12 (or early termination), and were transmitted to a central laboratory for interpretation.

LIC (mg/g dw) for deferiprone and deferoxamine treatment groups for the ITT population (primary endpoint). (A) LIC over time. Data are shown as means with error bars showing SD. (B) Mean change in LIC from baseline at month 12. Data are shown as means with error bars showing SE. A t test was used to calculate the P value. LIC was measured using R2* MRI scans, which were performed at screening/baseline, month 6, and month 12 (or early termination), and were transmitted to a central laboratory for interpretation.

Close Modal

or Create an Account

Close Modal
Close Modal